Ibucalmin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ibucalmin

Property Description
Active ingredient Ibuprofen
Form Film-coated tablets, oral capsule, oral suspension
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use Symptomatic relief of pain, fever, and inflammation
Origin Synthetic propionic acid derivative

Ibucalmin is a pharmaceutical product primarily used for the general symptomatic relief of pain, fever, and inflammation. It is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), a major class of non-narcotic analgesics.


What Type of Medicine is Ibucalmin? (Definition and Classification)

Ibucalmin is a trade name for a product containing Ibuprofen, which belongs to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), defining its broad functionality across pain, temperature, and swelling management. Its primary general purpose is to provide a comprehensive triple action relief: analgesic (pain relief), antipyretic (fever reducing), and anti-inflammatory. Ibuprofen is widely used for its anti-inflammatory properties. This medication is clinically recognized for its reliable efficacy in managing acute general discomfort, such as feverish colds.


Composition, Origin, and Available Forms (Substance Identity)

The sole active ingredient in Ibucalmin is Ibuprofen, a synthetic compound that is chemically categorized as a propionic acid derivative. This medication is manufactured as a single-ingredient product and is designed primarily for oral administration in common dosage forms such as film-coated tablets, oral capsules, or oral suspension for systemic effect. Ibuprofen is an established medicinal substance with well-defined therapeutic applications. The formulation is positioned to offer flexibility in administration, particularly through the availability of the oral suspension, which is often suitable for specific patient groups.


What is the General Purpose of Ibucalmin? (High-Level Action)

The general function of Ibucalmin is to disrupt the body's response to pain and inflammation by regulating key chemical signals. It achieves this by the nonselective inhibition of cyclooxygenase (COX) enzymes, which reduces the production of prostaglandins—substances responsible for mediating fever, pain, and swelling. By disrupting the formation of these mediators, Ibucalmin successfully suppresses pain signals, lowers the body's temperature set point, and reduces inflammation, achieving its primary goal of generalized symptomatic relief. Propionic acid derivatives like Ibuprofen alter these inflammatory pathways through this mechanism.

Regulatory References

  1. EMA EPAR/Monograph

What side effects are possible with Ibucalmin?

Possible side effects and safety information: Ibucalmin

Ibucalmin, which contains ibuprofen lysinate (a nonsteroidal anti-inflammatory drug or NSAID), is generally well-tolerated, especially when used at the lowest effective dose for the shortest duration. However, like all medications, it may cause side effects. Most common side effects are gastrointestinal.


Common and Less Common Side Effects

System Common Side Effects (May affect up to 1 in 10 people)
Gastrointestinal Heartburn, indigestion, nausea, vomiting, abdominal pain, diarrhea, constipation, flatulence.
Nervous System Headache, dizziness, mild drowsiness.

Less common effects can include skin rash, worsening of asthma, and fluid retention (edema) which may lead to swelling in the limbs.


Serious Safety Risks

NSAIDs carry a risk of serious cardiovascular and gastrointestinal events, particularly with high doses or long-term use. This risk includes stomach or intestinal bleeding, ulceration, or perforation which can be fatal. Signs of this include bloody, black, or tarry stools or vomiting blood.

Ibucalmin may also slightly increase the risk of heart attack or stroke in some patients, especially those with pre-existing heart conditions. Do not use this product if you have a history of severe heart failure, active gastrointestinal bleeding or ulcer, or a severe allergic reaction to aspirin or other NSAIDs.

Patients should seek immediate medical attention if they experience chest pain, sudden numbness, slurred speech, or signs of an allergic reaction (e.g., swelling of the face, throat, or difficulty breathing). Prolonged use may require monitoring of kidney and liver function.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory documentation for Ibucalmin (Ibuprofen) overdose establishes a profile based on documented clinical effects across the gastrointestinal (GI), central nervous system (CNS), and renal systems. Officially listed manifestations include common disturbances such as nausea, vomiting, epigastric pain, headache, and dizziness, alongside signs of CNS depression. Severe outcomes, including coma, seizures, and acute renal failure, are reported in the official prescribing information, particularly following massive ingestions, which are doses exceeding 400 mg/kg in children.

Regulatory authorities mandate that individuals seek immediate medical attention or contact a Poison Control Center right away. This action is required upon exceeding the maximum dose, even if symptoms are not yet apparent. Management is strictly defined as symptomatic and supportive, as no specific antidote is known for Ibuprofen overdose. Supportive procedures outlined in official guidelines may include the use of activated charcoal for large ingestions and the administration of benzodiazepines to manage convulsions. This framework defines the expected clinical presentation and establishes the necessary public health response based on official label text.

Therapeutic Uses of Ibucalmin

What Ibucalmin Treats: Main Uses and Benefits

Ibucalmin is an established agent used in situations involving certain distressing symptoms across multiple therapeutic domains. It provides support that helps ease the overall symptom load during acute episodes. This medication is commonly used across conditions presenting with acute episodes and is used for managing symptoms related to physical discomfort and systemic imbalance.

Key Symptom Relief and Therapeutic Benefits

The primary therapeutic benefit is to help address the symptom cluster of pain, fever, and inflammation, making it relevant in contexts marked by increased discomfort. This contributes to improved comfort during periods of heightened symptoms by addressing symptoms related to conditions like general headaches, backache, dental pain, sprains, and menstrual cramps. It is generally applied in scenarios where additional management of discomfort is required.

“It may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.”

Quick Fact: Relief for Episodic Discomfort
Ibucalmin is relevant for easing symptoms related to inflammatory or irritative states and is often used during phases when symptoms become more noticeable, particularly for mild-to-moderate discomfort.

The medication is used for managing symptoms related to acute presentations, including symptoms that create noticeable functional strain associated with common ailments, injury, or inflammatory conditions.

Eligibility and Restrictions for Use

Ibucalmin (Ibuprofen) eligibility is defined by regulatory bodies through specific contraindications and conditional use requirements.

Populations for Whom Use is Contraindicated

Use is prohibited for individuals with known hypersensitivity to ibuprofen, aspirin, or any other NSAID, or those who have experienced asthma or allergic reactions following their use. Absolute non-eligibility also applies to patients with severe heart failure (NYHA Class IV), severe renal or hepatic failure, or a history of recurrent peptic ulcer/gastrointestinal haemorrhage. The medicine is also contraindicated in the third trimester of pregnancy (after 30 weeks gestation) and for treating pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.


Age-Related and Conditional Eligibility

Adults and adolescents mathbfge 12 years of age are the generally approved population for standard formulations. Eligibility for younger children (typically mathbfge 6 months) is conditional and depends on weight-based pediatric forms. Older adults require use with caution at the lowest effective dose due to an officially documented increased risk of adverse reactions. Patients with uncontrolled hypertension, mild-to-moderate organ impairment, or a history of inflammatory bowel diseases must also use the medicine under specific restrictions and consultation.

What should I know about interactions with other medicines?

Ibucalmin interacts with several medicines and substances, and these interaction patterns are officially documented in regulatory information. Combinations with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, are explicitly contraindicated due to a significantly increased risk of gastrointestinal bleeding or ulceration. Use is also prohibited in the setting of peri-operative pain for coronary artery bypass graft (CABG) surgery.

Several documented pharmacodynamic interactions exist. Co-administration with Anticoagulants (like Warfarin), Corticosteroids, or SSRIs may lead to a heightened risk of gastrointestinal hemorrhage. Ibucalmin can also diminish the effectiveness of Anti-hypertensives and increase the risk of nephrotoxicity when combined with diuretics or immunosuppressants (such as Ciclosporin or Tacrolimus).

Exposure-altering interactions are also noted. Ibuprofen reduces the renal clearance of Lithium and Methotrexate, which can lead to officially documented elevated plasma concentrations of these medicines. For anti-platelet therapy, an administration separation rule is necessary: Ibuprofen should be taken at least 8 hours before or 30 minutes after low-dose, immediate-release Aspirin. Furthermore, consuming alcohol increases the overall risk of gastrointestinal bleeding. These risks are notably higher for elderly patients and individuals with impaired organ function.

Mechanism of Action

How Ibucalmin Works

Targeted Inhibition of Cyclooxygenase (COX) Enzymes

The mechanism of action centers on the reversible, nonselective competitive inhibition of the Cyclooxygenase (COX) enzymes . By competing with arachidonic acid, the molecule limits the production of key eicosanoid mediators, notably prostaglandin E2 ( PGE2), which are physiological transmitters that modulate peripheral sensation and vascular tone. This molecular interference modifies an early step in the COX cascade that shapes downstream physiological outcomes.


Modulation of Central and Peripheral PGE2 Signaling

The enzyme inhibition modulates biological systems both centrally and peripherally. In peripheral tissue, the reduction of PGE2 results in the modulation of the sensitization threshold of nociceptors and a decrease in localized tissue fluid accumulation. Simultaneously, the molecule modulates the central system by reducing PGE2 concentration in the hypothalamus, facilitating the adjustment of the elevated thermoregulatory set point.

Dosage and Administration Information

The administration of Ibucalmin is strictly governed by regulatory guidelines that standardize dosage, frequency, route, and duration of use. The medicine is primarily delivered via the Oral route (as tablets, capsules, or suspension) and, in controlled clinical settings, is approved for Intravenous (IV) injection. The core principle for use across all populations and forms is to employ the lowest effective dosage for the shortest duration necessary, as outlined in official labeling.


Official Dosing and Frequency

Population/Use Standard Regimen Maximum Daily Dose
Adult Oral (Acute) 200 mg to 400 mg every 4 to 6 hours. 1200 mg
Adult Oral (Prescription) 400 mg to 800 mg in divided doses. 3200 mg
Adult IV 400 mg to 800 mg every 6 hours. 3200 mg

IV administration must be administered as an infusion over at least 30 minutes and requires dilution before use. The oral suspension must be shaken well prior to measurement with an accurate dosing device.


Population and Contextual Use

For pediatric patients (starting at 6 months of age), dosing is calculated based on body weight (typically 5 mg/kg to 10 mg/kg per dose), with the total daily intake not to exceed 40 mg/kg or 2400 mg. Older adults and patients with mild-to-moderate organ impairment often require a reduced starting dose. Oral forms may be consumed with food or milk for patient comfort. If a regular dose is missed, regulatory guidance explicitly states not to take a double dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Ibucalmin

Evidence for Symptomatic Relief of Acute Pain

Research has explored the use of the active ingredient, Ibuprofen, in addressing outcomes related to common acute physical discomforts, such as headache, muscle sprains, and pain after dental procedures. This area primarily involves short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. Researchers examined outcomes related to physical discomfort, specifically monitoring changes in pain intensity and observing the time elapsed to reach a measured change.

Regulatory summaries describe the overall high consistency of these short-term findings across the wide body of acute pain research, including studies in Adults, Adolescents, and Children. What remains uncertain is related to its limitations, as there is limited information for long-term outcomes regarding the sustained management of chronic, non-inflammatory pain.


Evidence for Fever Reduction (Antipyretic Effects)

The use of this medicine was evaluated in numerous Randomized Controlled Trials (RCTs) for its effect on high temperature, often comparing it to other agents studied for similar outcomes, such as paracetamol (acetaminophen). Studies researched outcomes related to systemic or functional imbalance, including the reduction in body temperature and the time taken for temperature normalization (defervescence).

When compared to paracetamol in certain trials, the findings were mixed regarding which agent was associated with a more substantial or faster temperature change. Comparative evidence is lacking for a firm conclusion on the superiority of one agent over the other, and research does not provide evidence whether an individual will respond similarly when using both agents in an alternating fashion, as that area of study remains heterogeneous.


Evidence in Specialized and Specific Populations

Research was evaluated in special populations. For Children, evidence focusing on acute pain and fever is extensive and aligns with the evidence supporting its availability in liquid formulations. A highly specialized application was observed in Premature Infants for Patent Ductus Arteriosus (PDA), but this is restricted to a specialized, non-oral formulation. For Older Adults, data for certain groups remain insufficient, particularly for those with defined comorbid conditions.

Frequently Asked Questions (FAQ)

Common questions about Ibucalmin (FAQ)

Q: Are there any specific foods or drinks to avoid when using Ibucalmin?

Official product information notes that use of alcohol is advised against because it can increase the risk of stomach bleeding. Official product information notes that taking the medicine with food or milk may help reduce potential gastrointestinal upset.

Q: Can Ibucalmin be taken with blood pressure medication?

Regulatory labels contain warnings about potential interactions with various blood pressure medications, including common types like ACE inhibitors and diuretics. Official product information indicates that concurrent use may reduce the effectiveness of the blood pressure medication or increase the potential for kidney-related side effects.

Q: Is Ibucalmin a long-term or a short-term treatment medication?

Official guidance advises using the lowest effective dose for the shortest duration of time necessary to meet treatment goals. Non-prescription use is commonly limited to 10 days, and consulting a healthcare professional is necessary for continued use.

Q: Are there any documented drug-drug interactions with common over-the-counter medicines?

Regulatory documents include warnings about interactions with other medicines, even common over-the-counter types like aspirin. Taking this medication close to low-dose aspirin can interfere with its blood-thinning effects, and co-administration with other nonsteroidal anti-inflammatory drugs (NSAIDs) is generally cautioned against in regulatory documents.

Q: What is the general difference between prescription and over-the-counter Ibucalmin formulations?

Official regulatory documents indicate that the main difference is the maximum allowable dosage. The maximum daily dose for over-the-counter (OTC) use is limited, while the maximum daily dose for prescription use can be significantly higher under a healthcare professional's direct supervision.

Q: Can I take Ibucalmin if I am also using anti-depressants?

Regulatory product labels include specific warnings about using this medication concurrently with certain types of anti-depressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs). Regulatory information notes this combination may be associated with an increased risk of bleeding.

Q: How does the mechanism of action of Ibucalmin differ from common NSAIDs?

According to regulatory-cited pharmacological data, Ibucalmin is categorized as a nonsteroidal anti-inflammatory drug (NSAID). Its mechanism of action involves the temporary blocking of the body's cyclooxygenase (COX) enzymes, which stops the production of pain and inflammation signals called prostaglandins.

Q: What is the purpose of the black box warning or equivalent regulatory cautions, if any?

The regulatory boxed warnings are required to highlight serious safety concerns. They caution about the potential for serious cardiovascular events, such as heart attack or stroke, and the risk of serious gastrointestinal complications, including bleeding, ulceration, or perforation of the stomach or intestines.

Q: What should I do if I think I am experiencing an interaction (general, non-advice)?

Official patient labeling advises that if serious symptoms are experienced, use of the medication should be stopped and medical help sought immediately. These signs include chest pain, sudden weakness, or symptoms of stomach bleeding, such as passing bloody or black stools.

Q: Does Ibucalmin have any known impact on the ability to drive or operate machinery?

Official product information states that the medication may cause side effects such as dizziness or drowsiness (somnolence). If a person experiences these effects, regulatory guidance advises against driving or operating machinery.

Q: What is the definition of 'maximum recommended duration of use' for Ibucalmin?

The maximum recommended duration for non-prescription use is typically 10 days for managing pain and fever. Patients are advised to consult a healthcare professional if symptoms continue beyond this period.

Q: Are there any official reports of unexpected side effects of Ibucalmin?

Regulatory documents categorize and list the known adverse reactions (side effects) into groups such as Common, Uncommon, and Rare. Official labeling advises patients to notify a healthcare professional about any new or unexplained symptoms they experience.

Q: Is it true that Ibucalmin can affect blood clotting?

Yes, regulatory warnings note the potential for the medication to affect the body’s clotting mechanisms. It may increase the risk of serious cardiovascular thrombotic events (blood clots) and can also interfere with the antiplatelet effects of low-dose aspirin.

Q: What are the main findings from long-term safety studies of Ibucalmin?

Long-term safety findings, as cited in regulatory warnings, link extended use or high doses to an increased risk of serious adverse events. These findings primarily concern the heightened potential for heart attack, stroke, and severe gastrointestinal complications like bleeding.

Q: What should I know about taking Ibucalmin before a surgical procedure?

Regulatory documents strictly state that the medication is contraindicated (advised against use) around the time of coronary artery bypass graft (CABG) surgery. For any other planned surgical procedure, a healthcare professional should be consulted beforehand.

Q: How quickly can I expect Ibucalmin to start working?

While official documents do not specify an exact onset time in minutes, the recommended dosing interval for acute pain is typically every 4–6 hours. This frequency reflects the typical duration of relief expected from a dose.

Q: How long does the effect of one dose of Ibucalmin typically last?

The duration of the therapeutic effect for a single dose is approximately 4–6 hours, which aligns with the recommended interval for taking the medication for pain or fever relief.

Q: Why is Ibucalmin described as a 'non-opioid' medication?

Official classification confirms that this medication is not scheduled as a controlled substance by regulatory bodies. It is generally not associated with physical dependence or withdrawal symptoms, which distinguishes it from opioid medications.

Q: Is Ibucalmin available without a prescription in some places?

Yes, regulatory dosing guidelines distinguish between Over-The-Counter (OTC) use and prescription use. This means it is available without a prescription in many places, typically in lower dosage forms.

Q: Does Ibucalmin affect or interact with birth control pills?

Regulatory-cited information suggests potential interactions. Concurrent use with certain combined hormonal contraceptives may be associated with an increased risk of venous thromboembolism (blood clots) and hyperkalemia (high potassium).

Q: Is Ibucalmin described as having a potential for dependency?

Regulatory information indicates that the active substance is not classified as a controlled substance. It is generally not considered to lead to substance use disorder or cause withdrawal symptoms upon discontinuation.

Q: Are there any known interactions between Ibucalmin and herbal supplements?

Regulatory-supported advice notes that caution is advised with certain herbal supplements, especially those with known blood-thinning effects like garlic or ginkgo biloba. Combining these may increase the risk of bleeding.

Q: Is there a generic version of Ibucalmin available?

Yes, the active ingredient is approved and available under its generic name, which is listed in official regulatory databases. This confirms the existence of generic versions of the drug.

Q: Does Ibucalmin interact with any common diabetes medications?

Regulatory labeling indicates that patients with underlying risk factors, such as diabetes mellitus, are advised to exercise careful consideration and monitoring, especially during long-term treatment, due to potential increases in adverse events like kidney issues.

Q: Can women who are nursing or breastfeeding use Ibucalmin?

Regulatory-cited data indicates that due to the extremely low levels found in breastmilk and its known safety profile, the active ingredient is often considered a preferred choice for use while nursing. Consultation with a healthcare professional is still advised.

Q: Do I need to stop taking other vitamins or minerals when using Ibucalmin?

Regulatory product labeling advises patients to inform their healthcare professional about all other medicines, vitamins, and herbal supplements before starting treatment. This allows a professional to assess for any potential interactions.

Q: Why do some forums call Ibucalmin a pro-drug?

Official regulatory documents describe the active substance as the primary compound that exerts the pharmacological effect by inhibiting COX enzymes. It is not generally classified as an inactive pro-drug that requires the body to metabolize it to become active.

Q: Is Ibucalmin listed as a controlled substance?

No, the active substance is not classified and listed in any of the Schedules (I-V) of controlled substances by the U.S. Drug Enforcement Administration (DEA).

How should Ibucalmin be stored and disposed of?

Storage and Disposal of Ibucalmin (Ibuprofen)

Storage and disposal requirements for Ibuprofen (the active ingredient in Ibucalmin) are defined by official regulatory documentation to ensure product stability and safety.

Storage Component Official Regulatory Requirement
Temperature Store below 25 C (for bottled presentations).
Handling/Protection Keep the bottle tightly closed to protect from moisture.
Packaging Notes Blister packs generally do not require special storage conditions.
Stability The official shelf life is typically 3 to 5 years, depending on the formulation.
Disposal Any unused medicinal product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste.

These conditions ensure the medicine maintains its quality throughout its labeled shelf life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ibucalmin found in:

A-Z Index: